Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Zito

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Plos One|August 13, 2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxelLucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint InhibitorsHarriet M Kluger, Christopher R Zito, Gabriela Turcu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain MetastasisLucia B Jilaveanu, Fabio Parisi, Meaghan L Barr, et al.
Cellular and Molecular Life Sciences : CMLS|June 23, 2022
Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanomaVictor O Oria, Hongyi Zhang, Christopher R Zito, et al.
Cancer|November 27, 2019
PLEKHA5 regulates tumor growth in metastatic melanomaHongyi Zhang, Huifang Zhu, Gang Deng, et al.
Cancers|April 3, 2021
Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune CellsThuy T Tran, Chetan K Rane, Christopher R Zito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialHarriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Plos One|August 13, 2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxelLucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint InhibitorsHarriet M Kluger, Christopher R Zito, Gabriela Turcu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain MetastasisLucia B Jilaveanu, Fabio Parisi, Meaghan L Barr, et al.
Cellular and Molecular Life Sciences : CMLS|June 23, 2022
Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanomaVictor O Oria, Hongyi Zhang, Christopher R Zito, et al.
Cancer|November 27, 2019
PLEKHA5 regulates tumor growth in metastatic melanomaHongyi Zhang, Huifang Zhu, Gang Deng, et al.
Cancers|April 3, 2021
Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune CellsThuy T Tran, Chetan K Rane, Christopher R Zito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialHarriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Pageof 2